Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 01 Aug 2019
Proposal to enhance the transparency of CADTH’s review reports and recommendations
31 July 2019 - CADTH is committed to increasing the transparency of its health technology assessment processes. ...
Posted by Michael Wonder on 27 May 2019
'You disappointed us': Why is Canada opposing more transparency in drug prices?
25 May 2019 - Pharma industry says high prices are necessary to cover costs. Some nations want to see the data. ...
Posted by Michael Wonder on 18 Mar 2018
Costco under investigation by Ontario forensic team over drug company payments
16 March 2018 - Rebates not allowed in province in bid to drive down overall price of generics. ...
Posted by Michael Wonder on 30 Sep 2017
Blacked-out information reveals secret world of drug prices
30 September 2017 - This week, the Patented Medicine Prices Review Board ruled the Canadian price of the drug Soliris is ...
Posted by Michael Wonder on 01 Mar 2016
CADTH to provide drug plans with copies of CDR submission or resubmission materials
25 February 2016 - CADTH has begun providing authorized recipients from the CDR-participating drug plans with copies of all category 1 ...
Posted by Michael Wonder on 26 Feb 2016
Update on procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: mandatory disclosure of a submitted drug price
25 February 2016 - In late September 2015, CADTH invited stakeholder comments and feedback on proposed revisions to the CADTH Common ...